Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Shamliyan TA, Kane RL, Taylor FR. Migraine in adults: preventive pharmacologic treatments. Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review No. 103. 2013 Authors' objectives To assess comparative effectiveness and safety of preventive pharmacologic treatments for community-dwelling adults with episodic or chronic migraine. Authors' conclusions For chronic migraine, onabotulinumtoxin A reduced migraine attacks but increased the risk of adverse effects and treatment discontinuation due to adverse effects. For episodic migraine, approved drugs are effective but increase risk of adverse effects and treatment discontinuation due to adverse effects. Some off-label beta blockers and angiotensin inhibiting drugs are effective without bothersome harms and therefore offer the best benefits-to-harms ratio. We could not determine the long-term (i.e., trials of more than 3 months' duration), preventive benefits and adherence with drugs. Evidence on improving quality of life was inconsistent across individual drugs. Evidence for individualized treatment decisions is very
limited. Future research should examine the role of patient characteristics on drug benefits and safety. Indexing Status Subject indexing assigned by CRD MeSH Adults; Migraine Disorders Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence AHRQ, Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA Email: AHRQTAP@ahrq.hhs.gov AccessionNumber 32013000723 Date abstract record published 14/10/2013 |